Single-Agent Drug Proves Effective in Previously-Treated Marginal Zone Lymphoma

12/20/17

A single-agent therapy is an effective chemotherapy-free option for patients with marginal zone lymphoma previously exposed to conventional monotherapy, according to a study presented recently at the American Society of Hematology Annual Meeting and Exposition (December 8-12, 2017; Atlanta, GA).

The study reported additional analyses from a phase 2 study of patients with relapsed/refractory marginal zone lymphoma whose prior treatment included one or more CD20-containing regimens. Sixty-three enrolled patients received oral ibrutinib (560 mg once daily) for up to 3 years or until disease progression or unacceptable toxicity.

Single-agent ibrutinib showed a trend toward higher overall response rate and median progression-free survival, as well as a quicker response, in patients with relapsed/refractory marginal zone lymphoma who had previously received rituximab monotherapy compared with patients who received rituximab-based chemoimmunotherapy, researchers reported.

The overall response rate for patients who had received rituximab only was 69% compared with 46% for patients who had received rituximab-based chemoimmunotherapy. The estimated 18-month progression-free survival rate was 68% for patients who had received prior rituximab monotherapy and 35% for those who had received prior rituximab-based chemoimmunotherapy, according to the study.

“In all cases,” researchers wrote, “continued treatment with ibrutinib resulted in increased clinical benefit.”

-----

Related Content

Novel Prognostic Index Designed for Patients With MZL

Clinical Pathways, Targeted Therapies Likely to Shape Future MZL Treatment

-----

Additionally, researchers reported that MYD88 and TNFAIP3 mutations in the BCR-NFkB signaling pathway were positively linked with patient response. However, mutations in NOTCH2 and KMT2D, which are not involved in BCR-NFkB signaling, were negatively associated with patient response. —Jolynn Tumolo